OncoMatch/Clinical Trials/NCT07693452
Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
Is NCT07693452 recruiting? Yes, currently enrolling (Jul 2026). This Phase 2 trial studies Metformin for appendiceal mucinous neoplasm.
Treatment: Metformin — This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritoneal (PMP) secondary to appendiceal mucinous neoplasms (AMNs).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California, Irvine · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07693452 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify